Leon Scott Jr.

Array ( [id] => 17563211 [patent_doc_number] => 20220127360 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => TETRAVALENT BISPECIFIC ANTIBODY AGAINST PD-1 AND VEGF, PREPARATION METHOD THEREFOR, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/571894 [patent_app_country] => US [patent_app_date] => 2022-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28145 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17571894 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19464180 [patent_doc_number] => 20240317849 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => NUCLEIC ACIDS ENCODING ANCHOR MODIFIED ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/257793 [patent_app_country] => US [patent_app_date] => 2021-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49494 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18257793 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17685946 [patent_doc_number] => 20220193238 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => ANTI-IL5R ANTIBODY FORMULATIONS [patent_app_type] => utility [patent_app_number] => 17/552383 [patent_app_country] => US [patent_app_date] => 2021-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18472 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -56 [patent_words_short_claim] => 132 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17552383 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18955241 [patent_doc_number] => 20240043568 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => DEVELOPMENT OF NEW TUMOR ENGAGER THERAPEUTIC DRUG AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/265114 [patent_app_country] => US [patent_app_date] => 2021-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26627 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 193 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18265114 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19018983 [patent_doc_number] => 20240075154 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => ENGINEERED ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/253677 [patent_app_country] => US [patent_app_date] => 2021-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7685 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18253677 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17641988 [patent_doc_number] => 20220169726 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => ANTI-SIRPalpha MONOCLONAL ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/530302 [patent_app_country] => US [patent_app_date] => 2021-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16422 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17530302 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18860321 [patent_doc_number] => 20230414755 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => METHODS AND COMPOSITIONS RELATING TO GENETICALLY ENGINEERED CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS [patent_app_type] => utility [patent_app_number] => 18/036698 [patent_app_country] => US [patent_app_date] => 2021-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23366 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -69 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18036698 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17776600 [patent_doc_number] => 20220242949 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => ANTI-CD166 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/522189 [patent_app_country] => US [patent_app_date] => 2021-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39261 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17522189 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17428426 [patent_doc_number] => 20220056134 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => METHODS OF MAKING ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/454015 [patent_app_country] => US [patent_app_date] => 2021-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29731 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17454015 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18842717 [patent_doc_number] => 20230405121 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => ENGINEERED IPSC AND IMMUNE EFFECTOR CELLS FOR HETEROGENOUS TUMOR CONTROL [patent_app_type] => utility [patent_app_number] => 18/250735 [patent_app_country] => US [patent_app_date] => 2021-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54923 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -67 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18250735 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20173022 [patent_doc_number] => 12391754 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-19 [patent_title] => Fusion protein of single domain antibody and procoagulant [patent_app_type] => utility [patent_app_number] => 17/452033 [patent_app_country] => US [patent_app_date] => 2021-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 28 [patent_no_of_words] => 3925 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17452033 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17428446 [patent_doc_number] => 20220056154 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => Bispecific Antibody Compositions and Methods for Treating COVID-19 [patent_app_type] => utility [patent_app_number] => 17/499030 [patent_app_country] => US [patent_app_date] => 2021-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49744 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17499030 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18893823 [patent_doc_number] => 20240009308 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => CHIMERIC ANTIGEN RECEPTOR COMPRISING NOVEL CO-STIMULATORY DOMAIN AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/025558 [patent_app_country] => US [patent_app_date] => 2021-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13106 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18025558 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18529996 [patent_doc_number] => 20230235064 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => BISPECIFIC IMMUNE CELL ENGAGERS WITH BINDING SPECIFICITY FOR HLA-G AND ANOTHER ANTIGEN [patent_app_type] => utility [patent_app_number] => 18/009686 [patent_app_country] => US [patent_app_date] => 2021-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 98539 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18009686 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18468885 [patent_doc_number] => 20230203168 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => Dual EGFR-MUC1 Chimeric Antigen Receptor T Cells [patent_app_type] => utility [patent_app_number] => 18/000312 [patent_app_country] => US [patent_app_date] => 2021-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24648 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18000312 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17272997 [patent_doc_number] => 20210379195 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => METHODS FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION [patent_app_type] => utility [patent_app_number] => 17/244864 [patent_app_country] => US [patent_app_date] => 2021-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58309 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17244864 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18612383 [patent_doc_number] => 20230279115 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => SINGLE VARIABLE DOMAIN ANTIBODY TARGETING HUMAN PROGRAMMED DEATH LIGAND 1 (PD-L1) AND DERIVATIVE THEREOF [patent_app_type] => utility [patent_app_number] => 17/996802 [patent_app_country] => US [patent_app_date] => 2021-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10308 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17996802 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17807495 [patent_doc_number] => 20220259330 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => TETRAVALENT BISPECIFIC ANTIBODY, PREPARATION METHOD THEREFOR, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/617516 [patent_app_country] => US [patent_app_date] => 2021-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27998 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17617516 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451517 [patent_doc_number] => 20230192795 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => IMMUNOCONJUGATES [patent_app_type] => utility [patent_app_number] => 17/996338 [patent_app_country] => US [patent_app_date] => 2021-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49404 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17996338 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18297923 [patent_doc_number] => 20230107609 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-06 [patent_title] => ANTI-PD-1 ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/913752 [patent_app_country] => US [patent_app_date] => 2021-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13119 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17913752 [rel_patent_id] =>[rel_patent_doc_number] =>)